Physician profile
Mohammad J Uddin
NPI 1679654917
$3,390.48
in general payments reported to CMS, 2019-2025
35 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $298 · 2021: $775 · 2022: $537 · 2023: $309 · 2024: $427 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $751.61 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $325.70 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $281.93 | 2020-2025 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $262.41 | 2019-2023 | Verquvo, Belsomra |
| Pfizer INC. | $221.74 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $220.21 | 2020-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $152.60 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $125.46 | 2019-2021 | |
| Amgen INC. | $80.35 | 2019-2025 | Evenity |
| Glaxosmithkline, LLC. | $78.24 | 2019-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $66.14 | 2021-2023 | |
| Allergan, INC. | $62.10 | 2019-2020 | |
| Astellas Pharma US INC | $61.64 | 2019 | |
| Amarin Pharma, INC. | $58.48 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $56.72 | 2024 | Rexulti |
| Dexcom, INC. | $51.71 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $45.64 | 2022-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.73 | 2020-2021 | |
| Gilead Sciences, INC. | $43.45 | 2019 | |
| Medtronic, INC. | $42.63 | 2023-2024 | Venaseal, Kyphon Express II Kyphopak Tray |
| Otsuka America Pharmaceutical, INC. | $33.58 | 2024 | Nuedexta |
| Sunovion Pharmaceuticals INC. | $29.11 | 2019 | |
| Inspire Medical Systems, INC. | $28.65 | 2024 | Inspire |
| Insulet Corporation | $26.49 | 2025 | Omnipod |
| Almatica Pharma LLC | $21.79 | 2025 | Loreev Xr |
| Exact Sciences Corporation | $20.99 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $19.37 | 2025 | Auvelity |
| Verona Pharma, INC. | $18.86 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2019 | |
| Sumitomo Pharma America, INC. | $15.96 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $15.62 | 2020 | |
| Shield Therapeutics INC | $14.24 | 2023 | Accrufer |
| Avanir Pharmaceuticals, INC. | $12.53 | 2021 | |
| Genentech USA, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.